100 related articles for article (PubMed ID: 24180451)
1. Reversal of vascular leak with imatinib.
Aman J; Peters MJ; Weenink C; van Nieuw Amerongen GP; Vonk Noordegraaf A
Am J Respir Crit Care Med; 2013 Nov; 188(9):1171-3. PubMed ID: 24180451
[No Abstract] [Full Text] [Related]
2. Reversal of vascular leak with imatinib: a role for IL-2?
Shin JI; Eisenhut M
Am J Respir Crit Care Med; 2014 Jul; 190(1):117-8. PubMed ID: 24983224
[No Abstract] [Full Text] [Related]
3. Reply: Reversal of vascular leak with imatinib: a role for IL-2?
van Nieuw Amerongen GP; Aman J; Vonk Noordegraaf A
Am J Respir Crit Care Med; 2014 Jul; 190(1):118. PubMed ID: 24983225
[No Abstract] [Full Text] [Related]
4. [Imatinib for pulmonary arterial hypertension].
Hoeper MM; Opitz C; Olschewski H; Ulrich S; Speich R; Behr J; Halank M; Wilkens H; Klose H; Lange TJ; Grünig E; Seeger W; Ewert R; Borst MM; Welte T; Rosenkranz S; Ghofrani HA
Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S151-4. PubMed ID: 25489685
[No Abstract] [Full Text] [Related]
5. Efficacy of imatinib mesylate in a case of Churg-Strauss syndrome: evidence for the pathogenic role of a tyrosine kinase?
Josselin-Mahr L; Werbrouck-Chiraux A; Garderet L; Cabane J
Rheumatology (Oxford); 2014 Feb; 53(2):378-9. PubMed ID: 23893665
[No Abstract] [Full Text] [Related]
6. EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations.
Bonifacio M; Binotto G; Calistri E; Maino E; Tiribelli M;
Ann Hematol; 2014 Jan; 93(1):163-4. PubMed ID: 24292539
[No Abstract] [Full Text] [Related]
7. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
Levitzki A
Annu Rev Pharmacol Toxicol; 2013; 53():161-85. PubMed ID: 23043437
[TBL] [Abstract][Full Text] [Related]
8. [Chronic myelogenous leukemia: management of treatment-related adverse events].
Takahashi N
Rinsho Ketsueki; 2012 Oct; 53(10):1581-8. PubMed ID: 23037730
[No Abstract] [Full Text] [Related]
9. Management of gastrointestinal stromal tumor: the imatinib era and beyond.
Parikh PM; Gupta S
Indian J Cancer; 2013; 50(1):31-40. PubMed ID: 23713042
[TBL] [Abstract][Full Text] [Related]
10. Imatinib in the treatment of nephrogenic systemic fibrosis.
Chandran S; Petersen J; Jacobs C; Fiorentino D; Doeden K; Lafayette RA
Am J Kidney Dis; 2009 Jan; 53(1):129-32. PubMed ID: 19012999
[TBL] [Abstract][Full Text] [Related]
11. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Thielen N; van der Holt B; Verhoef GE; Ammerlaan RA; Sonneveld P; Janssen JJ; Deenik W; Falkenburg JH; Kersten MJ; Sinnige HA; Schipperus M; Schattenberg A; van Marwijk Kooy R; Smit WM; Chu IW; Valk PJ; Ossenkoppele GJ; Cornelissen JJ
Ann Hematol; 2013 Aug; 92(8):1049-56. PubMed ID: 23572137
[TBL] [Abstract][Full Text] [Related]
12. Successful combination treatment of a patient with progressive juvenile localized scleroderma (morphea) using imatinib, corticosteroids, and methotrexate.
Inamo Y; Ochiai T
Pediatr Dermatol; 2013; 30(6):e191-3. PubMed ID: 23025697
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
14. Imatinib for the treatment of rheumatic diseases.
Paniagua RT; Robinson WH
Nat Clin Pract Rheumatol; 2007 Apr; 3(4):190-1. PubMed ID: 17396105
[No Abstract] [Full Text] [Related]
15. Imatinib treatment of generalized localized scleroderma (morphea).
Moinzadeh P; Krieg T; Hunzelmann N
J Am Acad Dermatol; 2010 Nov; 63(5):e102-4. PubMed ID: 20950732
[No Abstract] [Full Text] [Related]
16. A limited but necessary indication of stem cell transplantation for chronic myelogeneous leukemia in the era of tyrosine kinase inhibitors.
Imataki O
Transplantation; 2014 Jan; 97(1):e4-5. PubMed ID: 24374768
[No Abstract] [Full Text] [Related]
17. Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase.
Millot F; Claviez A; Leverger G; Corbaciglu S; Groll AH; Suttorp M
Pediatr Blood Cancer; 2014 Feb; 61(2):355-7. PubMed ID: 24106110
[TBL] [Abstract][Full Text] [Related]
18. Recurrence of severe pulmonary hypertension following the removal of a lung allograft.
Grinnan DC; Fairman P; Pinson J
Chest; 2007 Dec; 132(6):2057-8; author reply 2058. PubMed ID: 18079249
[No Abstract] [Full Text] [Related]
19. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
Rutkowski P; Gronchi A; Hohenberger P; Bonvalot S; Schöffski P; Bauer S; Fumagalli E; Nyckowski P; Nguyen BP; Kerst JM; Fiore M; Bylina E; Hoiczyk M; Cats A; Casali PG; Le Cesne A; Treckmann J; Stoeckle E; de Wilt JH; Sleijfer S; Tielen R; van der Graaf W; Verhoef C; van Coevorden F
Ann Surg Oncol; 2013 Sep; 20(9):2937-43. PubMed ID: 23760587
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
